FLUTIFORM

This brand name is authorized in Australia, Austria, Croatia, Cyprus, Finland, France, Germany, Hong Kong SAR China, Ireland, Israel, Japan, Netherlands, Nigeria, Poland, Romania, Singapore, Spain, UK.

Active ingredients

The drug FLUTIFORM contains a combination of these active pharmaceutical ingredients (APIs):

1	Fluticasone propionate UNII O2GMZ0LF5W - FLUTICASONE PROPIONATE
	Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically.
	Read more about Fluticasone
2	Formoterol fumarate dihydrate UNII W34SHF8J2K - FORMOTEROL FUMARATE
	Formoterol is a predominantly selective β2-stimulator. Formoterol has bronchodilator activity in patients with reversible obstructive airway diseases. In humans formoterol is effective in the prophylaxis of bronchospasm induced by methacholine challenge.
	Read more about Eformoterol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FLUTIFORM Pressurised inhalation, suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03AK11		R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AK Adrenergics and other drugs for obstructive airway diseases
Discover more medicines within R03AK11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10007Q, 10008R, 2827T
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	09101458, 09101464, 09101470, 09101487, 09101493, 09101501
ES	Centro de información online de medicamentos de la AEMPS	78536, 78537, 78538
FI	Lääkealan turvallisuus- ja kehittämiskeskus	135969, 149798, 173460
FR	Base de données publique des médicaments	61046628, 64789302
GB	Medicines & Healthcare Products Regulatory Agency	210195, 210198, 210207, 356509, 373918, 374488, 376652, 376654, 381346, 381348, 381350, 381352, 381354, 390895
HK	Department of Health Drug Office	62090, 62091, 62092
HR	Agencija za lijekove i medicinske proizvode	HR-H-341378137, HR-H-452322131, HR-H-702532961
IE	Health Products Regulatory Authority	33301, 33302, 33303, 33305
IL	מִשְׂרַד הַבְּרִיאוּת	7386, 7387, 7388
JP	医薬品医療機器総合機構	2290802G1023, 2290802G2020, 2290802G3026, 2290802G4022
NG	Registered Drug Product Database	B4-8373
NL	Z-Index G-Standaard, PRK	102547, 102555, 102563
PL	Rejestru Produktów Leczniczych	100289664, 100289670, 100289687
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W59644001, W59644002, W59645001, W59645002, W59646001, W59646002
SG	Health Sciences Authority	14549P, 14550P, 14551P